The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.
Edwin M. Posadas
No relevant relationships to disclose
Mourad Tighgohart
No relevant relationships to disclose
Yi-Tsung Lu
No relevant relationships to disclose
Dolores Di Vizio
No relevant relationships to disclose
David M. J. Hoffman
No relevant relationships to disclose
Leland Green
No relevant relationships to disclose
Margarit Sievert
No relevant relationships to disclose
Amy Oppenheim
No relevant relationships to disclose
Nancy P. Moldawer
No relevant relationships to disclose
Beatrice Knudsen
No relevant relationships to disclose
Michael Freeman
No relevant relationships to disclose
Neil Bhowmick
No relevant relationships to disclose
Andre Rogatko
No relevant relationships to disclose
Hsian-Rong Tseng
No relevant relationships to disclose
Leland WK Chung
Research Funding - Exelixis
Robert A. Figlin
No relevant relationships to disclose